Chang T, Ho P
Immune Netw. 2025; 25(1):e8.
PMID: 40078784
PMC: 11896656.
DOI: 10.4110/in.2025.25.e8.
Zhu M, Hu Y, Gu Y, Lin X, Jiang X, Gong C
Am J Cancer Res. 2025; 15(1):233-247.
PMID: 39949925
PMC: 11815375.
DOI: 10.62347/ZSOO2247.
Peter R, Sarwar M, Wang L, Chou P, Wang C, Wang Y
Pharm Res. 2025; 42(2):237-247.
PMID: 39904853
PMC: 11880055.
DOI: 10.1007/s11095-025-03820-8.
Yao P, Cao S, Zhu Z, Wen Y, Guo Y, Liang W
Int J Mol Sci. 2025; 26(2).
PMID: 39859489
PMC: 11765784.
DOI: 10.3390/ijms26020776.
Zhai Y, Liang X, Deng M
Chin J Cancer Res. 2025; 36(6):616-651.
PMID: 39802897
PMC: 11724180.
DOI: 10.21147/j.issn.1000-9604.2024.06.04.
Prostate Cancer's Silent Partners: Fibroblasts and Their Influence on Glutamine Metabolism Manipulation.
Honscheid P, Baretton G, Puhr M, Siciliano T, Israel J, Stope M
Int J Mol Sci. 2024; 25(17).
PMID: 39273225
PMC: 11394735.
DOI: 10.3390/ijms25179275.
Characteristics of Gut Microbiota and Fecal Metabolites in Patients with Colorectal Cancer-Associated Iron Deficiency Anemia.
Zhang Q, Wu W, Guo F, Li J, Jin Y, Cai G
Microorganisms. 2024; 12(7).
PMID: 39065088
PMC: 11279063.
DOI: 10.3390/microorganisms12071319.
Brucine Suppresses Malignant Progression of Prostate Cancer by Decreasing Sarcosine Accumulation via Downregulation of GNMT in the Glycine/sarcosine Metabolic Pathway.
Miao L, Liu Y, Chen W, Gao C, Zhang Y, Wei J
Cell Biochem Biophys. 2024; 82(3):2373-2385.
PMID: 38877335
DOI: 10.1007/s12013-024-01348-z.
Cancer immunometabolism: advent, challenges, and perspective.
Dang Q, Li B, Jin B, Ye Z, Lou X, Wang T
Mol Cancer. 2024; 23(1):72.
PMID: 38581001
PMC: 10996263.
DOI: 10.1186/s12943-024-01981-5.
Multi-omics landscape analysis reveals the pan-cancer association of arginine biosynthesis genes with tumor immune evasion and therapy resistance.
Tan Z, Li H, Huang Y, Fu S, Wang H, Wang J
Heliyon. 2024; 10(5):e26804.
PMID: 38468956
PMC: 10925990.
DOI: 10.1016/j.heliyon.2024.e26804.
Specific changes in amino acid profiles in monocytes of patients with breast, lung, colorectal and ovarian cancers.
Chagovets V, Starodubtseva N, Tokareva A, Novoselova A, Patysheva M, Larionova I
Front Immunol. 2024; 14:1332043.
PMID: 38259478
PMC: 10800720.
DOI: 10.3389/fimmu.2023.1332043.
Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic strategies.
Ambrosini G, Cordani M, Zarrabi A, Alcon-Rodriguez S, Sainz R, Velasco G
Cell Commun Signal. 2024; 22(1):36.
PMID: 38216942
PMC: 10790277.
DOI: 10.1186/s12964-023-01462-0.
Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
Dai X, Shi X, Luo M, Li P, Gao Y
BMC Cancer. 2023; 23(1):1241.
PMID: 38104097
PMC: 10724921.
DOI: 10.1186/s12885-023-11707-3.
Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity.
Zheng Y, Yao Y, Ge T, Ge S, Jia R, Song X
J Exp Clin Cancer Res. 2023; 42(1):291.
PMID: 37924140
PMC: 10623764.
DOI: 10.1186/s13046-023-02845-4.
The subacute toxicity and underlying mechanisms of biomimetic mesoporous polydopamine nanoparticles.
Chen B, Hong S, Wang H, Shi Y, Wang P, Wang X
Part Fibre Toxicol. 2023; 20(1):38.
PMID: 37807046
PMC: 10560437.
DOI: 10.1186/s12989-023-00548-4.
Predicting lung adenocarcinoma prognosis, immune escape, and pharmacomic profile from arginine and proline-related genes.
Wang Z, Zhang J, Shi S, Ma H, Wang D, Zuo C
Sci Rep. 2023; 13(1):15198.
PMID: 37709932
PMC: 10502151.
DOI: 10.1038/s41598-023-42541-z.
Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer.
Zuo Z, Zhou Z, Chang Y, Liu Y, Shen Y, Li Q
Genes Dis. 2023; 11(1):218-233.
PMID: 37588202
PMC: 10425756.
DOI: 10.1016/j.gendis.2022.11.022.
Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N, Chai M, Zhu L, Liu J, Yu C, Huang X
Front Immunol. 2023; 14:1070953.
PMID: 37334367
PMC: 10272553.
DOI: 10.3389/fimmu.2023.1070953.
Advances in landscape and related therapeutic targets of the prostate tumor microenvironment.
Li D, Xu W, Chang Y, Xiao Y, He Y, Ren S
Acta Biochim Biophys Sin (Shanghai). 2023; 55(6):956-973.
PMID: 37294106
PMC: 10326416.
DOI: 10.3724/abbs.2023092.
Metabolic reprogramming in cancer: Mechanisms and therapeutics.
Nong S, Han X, Xiang Y, Qian Y, Wei Y, Zhang T
MedComm (2020). 2023; 4(2):e218.
PMID: 36994237
PMC: 10041388.
DOI: 10.1002/mco2.218.